These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34180301)

  • 1. Controllable Drug Delivery by Na+/K+ ATPase α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer.
    Yang Y; Feng Q; Ding C; Kang W; Xiao X; Yu Y; Zhou Q
    Technol Cancer Res Treat; 2021; 20():15330338211027898. PubMed ID: 34180301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a sodium pump Na
    Wang Q; Li SB; Zhao YY; Dai DN; Du H; Lin YZ; Ye JC; Zhao J; Xiao W; Mei Y; Xiao YT; Liu SC; Li Y; Xia YF; Song EW; Tang GH; Zhang WG; Li ZJ; Zheng XB; Cao DH; Li MZ; Zhong Q; Chen ZP; Qian CN; Fan W; Feng GK; Zeng MS
    J Control Release; 2018 Jul; 281():178-188. PubMed ID: 29777796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
    Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer.
    Liu L; Mu LM; Yan Y; Wu JS; Hu YJ; Bu YZ; Zhang JY; Liu R; Li XQ; Lu WL
    Int J Nanomedicine; 2017; 12():4163-4176. PubMed ID: 28615943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
    Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
    Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells.
    Ansari L; Derakhshi M; Bagheri E; Shahtahmassebi N; Malaekeh-Nikouei B
    Pharm Dev Technol; 2020 Jun; 25(5):601-609. PubMed ID: 32026739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer.
    Moammeri A; Abbaspour K; Zafarian A; Jamshidifar E; Motasadizadeh H; Dabbagh Moghaddam F; Salehi Z; Makvandi P; Dinarvand R
    ACS Appl Bio Mater; 2022 Feb; 5(2):675-690. PubMed ID: 35129960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12.
    Sun WL; Wang L; Luo J; Zhu HW; Cai ZW
    Cancer Sci; 2018 Oct; 109(10):3129-3138. PubMed ID: 30027574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
    Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
    J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
    Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
    Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method.
    Gubernator J; Lipka D; Korycińska M; Kempińska K; Milczarek M; Wietrzyk J; Hrynyk R; Barnert S; Süss R; Kozubek A
    PLoS One; 2014; 9(3):e91487. PubMed ID: 24621591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.
    Liu CW; Wu YT; Lin KJ; Yu TJ; Kuo YL; Chang LC
    Molecules; 2016 Jun; 21(6):. PubMed ID: 27258243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro evaluation of antitumor activity of sirolimus-encapsulated liposomes in breast cancer cells.
    Nandi U; Onyesom I; Douroumis D
    J Pharm Pharmacol; 2021 Mar; 73(3):300-309. PubMed ID: 33793879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers.
    Di-Wen S; Pan GZ; Hao L; Zhang J; Xue QZ; Wang P; Yuan QZ
    Int J Pharm; 2016 Mar; 500(1-2):54-61. PubMed ID: 26748365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.